This is a working overview of REV-ERB agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-11. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Since Operation Inherent Resolve began, U.S. airstrikes have been supported by Green Beret adviser teams, helping stop the advances of ISIL. Green Berets from the 5th SFG deployed to Jordan in support of OIR. On November 4, 2016, a small convoy carrying Green Berets was returning to the base after a training exercise when a Jordanian guard, after waving the first vehicle through the entry control point at the base, then opened fire on the second vehicle killing 2 Green Berets, U.S. troops from the vehicle behind opened fire, another Green Beret was killed but a fourth, who was wounded, shot the Jordanian, severely wounding him.
In 2018, the International Union for Conservation of Nature (IUCN) assessed the white shark as vulnerable worldwide, citing a population decline of 30–49% since approximately 1859. The species was further described as "moderately depleted" in 2021. The biggest threats to white sharks are accidental catching in fishing nets and the use of shark control measures—such as nets and traps—near beaches in Australia and South Africa. They nevertheless maintain a high survival rate when released from such gear. To regulate international trade, the species is listed under CITES Appendix II, requiring permits for the exchange of any specimens or parts. While a 2025 study estimated the global population at a minimum of roughly 5,800 individuals, co-author Gavin Naylor suggests the actual figure may be closer to 20,000.
Magic numbers of 2, 8, 20, 28, 50, 82 and 126 have been observed for neutrons, and the next number is predicted to be 184. Protons share the first six of these magic numbers, and 126 has been predicted as a magic proton number since the 1940s. Nuclides with a magic number of each—such as 16O (Z = 8, N = 8), 132Sn (Z = 50, N = 82), and 208Pb (Z = 82, N = 126)—are referred to as "doubly magic" and are more stable than nearby nuclides as a result of greater binding energies. In the late 1960s, more sophisticated shell models were formulated by American physicist William Myers and Polish physicist Władysław Świątecki, and independently by German physicist Heiner Meldner (1939–2019). With these models, taking into account Coulomb repulsion, Meldner predicted that the next proton magic number may be 114 instead of 126. Myers and Świątecki appear to have coined the term "island of stability", and American chemist Glenn Seaborg, later a discoverer of many of the superheavy elements, quickly adopted the term and promoted it. Myers and Świątecki also proposed that some superheavy nuclei would be longer-lived as a consequence of higher fission barriers. Further improvements in the nuclear shell model by Soviet physicist Vilen Strutinsky led to the emergence of the macroscopic–microscopic method, a nuclear mass model that takes into consideration both smooth trends characteristic of the liquid-drop model and local fluctuations such as shell effects.
Sources: en.wikipedia.org
==== Lung ==== In both primary pulmonary hypertension, pulmonary embolism, and acute exacerbations of chronic obstructive pulmonary disease (COPD), right ventricular strain results in increased wall tension and may cause ischemia. Of course, patients with COPD exacerbations might also have concurrent myocardial infarction or pulmonary embolism, so care has to be taken to attribute increased troponin levels to COPD.
Part of the label's back catalog, which includes the pre-1984 Constellation back catalog, were licensed by EMI in 1996, with many of its releases and compilations being re-issued through The Right Stuff Records. In 2009, Unidisc Music purchased part of SOLAR's back catalog for Canada, US and South African territories. BMG owns the rights to part of the SOLAR catalog in the UK and Europe although the rights to SOLAR RECORDS as a trade mark and brand belong to the family of the late Dick Griffey according to the Intellectual Property Office.
=== Selenophosphate synthetase === The production of selenoprotein cannot occur without selenophosphate, which is produced by selenophosphate synthetase. Vertebrates including humans carry two versions of this enzyme, with one (SEPHS2) being a selenoprotein and the other (SEPHS1) replacing it with a threonine, though still with a vestigial SECIS element. Analysis of animal versions of this enzyme show that the original animal version is a selenoprotein, with SEPHS1 arising later through gene duplication. Among prokaryotes, most bacteria have a version with cystine instad of selenocystine, suggesting that this may be the ancestral state (which would avoid the chicken-and-egg problem). Some have two versions, one with Sec and the other with Cys. Archaea mostly have the Sec version.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.